SCHEMBL30765668

SCHEMBL30765668

CCCCOC(=O)Cn1c(-c2ccccc2)ncc(NCc2ccc(OC)cc2OC)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 4/20 0.46
KDM4C Q9H3R0 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
POLB P06746 1/20 0.41
TP53 P04637 2/20 0.41
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2D6 P10635 3/20 0.40
CLK4 Q9HAZ1 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
EED O75530 1/20 0.40
ELANE P08246 1/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765482 0.88 KDM4C (0.50) GAAMAPTKDM4CMEN1KMT2A
SCHEMBL30765526 0.87 KDM4C (0.46) GAAMAPTKDM4CMEN1KMT2A
SCHEMBL31558534 0.86 KDM4C (0.48) GAAMAPTKDM4CMEN1KMT2A
SCHEMBL30765600 0.85 KDM4C (0.44) GAAMAPTKDM4CMEN1KMT2A
SCHEMBL30766150 0.83 GAA (0.52) GAAL3MBTL1MAPTMEN1KMT2A
SCHEMBL30765667 0.83 GAA (0.56) GAAL3MBTL1MAPTMEN1KMT2A
SCHEMBL30765999 0.81 PDE4B (0.44) L3MBTL1MAPTKDM4CMEN1KMT2A
SCHEMBL30765790 0.80 L3MBTL1 (0.53) GAAL3MBTL1MAPTMEN1KMT2A
SCHEMBL30765723 0.79 MAPT (0.47) GAAL3MBTL1MAPTKDM4CMEN1
SCHEMBL30765584 0.77 GAA (0.50) GAAL3MBTL1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed